These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23539277)

  • 1. [Prolonged-release tapentadol for phantom pain. A case series].
    Kern KU; Bialas P; Fangmann D
    Schmerz; 2013 Apr; 27(2):174-81. PubMed ID: 23539277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
    Schwittay A
    MMW Fortschr Med; 2013 Jan; 155(1):64. PubMed ID: 23573727
    [No Abstract]   [Full Text] [Related]  

  • 3. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
    Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
    Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
    Schwittay A; Schumann C; Litzenburger BC; Schwenke K
    MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
    Agbalaka A; Schwenke K; Litzenburger B
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
    Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].
    Richter U; Waldmann-Rex S; Lehmann U
    Wien Klin Wochenschr; 2015 Jun; 127(11-12):477-87. PubMed ID: 25409951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
    Kern KU; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.